Therapeutic inertia in the management of dyslipidaemia and hypertension in incident type 2 diabetes and the resulting risk factor burden: Real‐world evidence from primary care-Reference-Cited by-同舟云学术

Therapeutic inertia in the management of dyslipidaemia and hypertension in incident type 2 diabetes and the resulting risk factor burden: Real‐world evidence from primary care

Published:2021-03-25 Issue:7 Volume:23 Page:1518-1531
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Ling Joanna Z.J.¹²,Montvida Olga¹,Khunti Kamlesh³^ORCID,Zhang Anthony L.²,Xue Charlie C.²^ORCID,Paul Sanjoy K.¹²^ORCID

Affiliation:

1. Melbourne EpiCentre University of Melbourne and Melbourne Health Melbourne Victoria Australia

2. School of Health and Biomedical Sciences RMIT University Melbourne Victoria Australia

3. Department of Health Sciences University of Leicester Leicester UK

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14364

Reference39 articles.

1. World Health Organization. Raised cholesterol. 2020; Global Health Observatory (GHO) data 2020.https://www.who.int/gho/ncd/risk_factors/cholesterol_text/en/. Accessed September 10 2020.

2. Global patterns of comprehensive cardiovascular risk factor control in patients with type 2 diabetes mellitus: Insights from the DISCOVER study

3. Cardiovascular Risk Factor Burden in People With Incident Type 2 Diabetes in the U.S. Receiving Antidiabetic and Cardioprotective Therapies

4. Multimorbidity, mortality, and HbA1c in type 2 diabetes: A cohort study with UK and Taiwanese cohorts

5. Eleven-year multimorbidity burden among 637 255 people with and without type 2 diabetes: a population-based study using primary care and linked hospitalisation data

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gamma-glutamyl transferase to high-density lipoprotein cholesterol ratio is a more powerful marker than TyG index for predicting metabolic syndrome in patients with type 2 diabetes mellitus;Frontiers in Endocrinology;2023-10-03

2. Cardiovascular disease and all-cause mortality associated with individual and combined cardiometabolic risk factors;BMC Public Health;2023-09-05

3. Position of the Polish Cardiac Society on therapeutic targets for LDL cholesterol concentrations in secondary prevention of myocardial infarctions;Kardiologia Polska;2023-08-26

4. GALIPDIA study: Reaching lipid targets in a population with type 2 diabetes (T2DM) from the Northwest of Spain;Endocrinología, Diabetes y Nutrición (English ed.);2023-01

5. Clinical Inertia and Diabetes Outcomes;The Diabetes Textbook;2023